Cargando…

Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21

BACKGROUND: The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies offer the best chance of disease control; however, the design of successful combin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Louise M. E., Holmes, Matthew, Michael, Joanne L., Scott, Gina B., West, Emma J., Scott, Karen J., Parrish, Christopher, Hall, Kathryn, Stäble, Sina, Jennings, Victoria A., Cullen, Matthew, McConnell, Stewart, Langton, Catherine, Tidswell, Emma L., Shafren, Darren, Samson, Adel, Harrington, Kevin J., Pandha, Hardev, Ralph, Christy, Kelly, Richard J., Cook, Gordon, Melcher, Alan A., Errington-Mais, Fiona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6604201/ https://www.ncbi.nlm.nih.gov/pubmed/31262361 http://dx.doi.org/10.1186/s40425-019-0632-y

Ejemplares similares

Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
por: Pandha, Hardev, et al.
Publicado: (2015)

Applications of coxsackievirus A21 in oncology
por: Bradley, Stephen, et al.
Publicado: (2014)

Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21
por: Annels, Nicola E, et al.
Publicado: (2015)

Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy?
por: Prestwich, Robin J, et al.
Publicado: (2008)

Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
por: Samson, Adel, et al.
Publicado: (2022)

Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition
por: Jennings, Victoria A., et al.
Publicado: (2019)

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
por: Simpson, Guy R, et al.
Publicado: (2016)

Reovirus-Mediated Cytotoxicity and Enhancement of Innate Immune Responses Against Acute Myeloid Leukemia
por: Hall, Kathryn, et al.
Publicado: (2012)

Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
por: Annels, Nicola E., et al.
Publicado: (2018)

Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients
por: West, Emma J., et al.
Publicado: (2022)

Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites
por: Jennings, VA, et al.
Publicado: (2014)

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
por: Turnbull, Samantha, et al.
Publicado: (2015)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
por: Heinemann, Lucy, et al.
Publicado: (2011)

Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia
por: Parrish, C, et al.
Publicado: (2015)

CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
por: Bozhanova, Galabina, et al.
Publicado: (2022)

Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors
por: Annels, Nicola E., et al.
Publicado: (2020)

Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy
por: Burnett, William J., et al.
Publicado: (2021)

Prime-boost using Separate Oncolytic Viruses in Combination with Checkpoint Blockade Improves Anti-tumor Therapy
por: Ilett, Elizabeth, et al.
Publicado: (2016)

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway
por: Twigger, Katie, et al.
Publicado: (2012)

Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
por: Samson, Adel, et al.
Publicado: (2018)

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics
por: Harrington, K.J., et al.
Publicado: (2010)

Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies
por: Roulstone, Victoria, et al.
Publicado: (2021)

Past, Present and Future of Oncolytic Reovirus
por: Müller, Louise, et al.
Publicado: (2020)

Coxsackievirus B3—Its Potential as an Oncolytic Virus
por: Geisler, Anja, et al.
Publicado: (2021)

Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model
por: Shafren, Darren, et al.
Publicado: (2014)

Measles virus causes immunogenic cell death in human melanoma
por: Donnelly, Oliver G, et al.
Publicado: (2011)

Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges
por: Liu, Huitao, et al.
Publicado: (2021)

SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus
por: Deng, James Z., et al.
Publicado: (2021)

2-Deoxyglucose, an Inhibitor of Glycolysis, Enhances the Oncolytic Effect of Coxsackievirus
por: Vorobyev, Pavel O., et al.
Publicado: (2022)

Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming
por: Steele, Lynette, et al.
Publicado: (2011)

Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo
por: Anesti, Anna-Maria, et al.
Publicado: (2010)

The Hitchhiker's Guide to Virotherapy
por: Donnelly, Oliver, et al.
Publicado: (2012)

Combination of intravenously delivered cavatak (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and tumor rechallenge
por: Yuan, Min, et al.
Publicado: (2015)

Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma
por: Okamura, Koji, et al.
Publicado: (2022)

Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18
por: Au, Gough G, et al.
Publicado: (2011)

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche
por: Müller, Louise M E, et al.
Publicado: (2021)

Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H
por: Hazini, Ahmet, et al.
Publicado: (2021)

Enhanced genomic stability of new miRNA-regulated oncolytic coxsackievirus B3
por: Liu, Huitao, et al.
Publicado: (2022)

Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
por: Kottke, Timothy, et al.
Publicado: (2021)

TLR1/2 orchestrate human plasmacytoid predendritic cell response to gram+ bacteria
por: Raieli, Salvatore, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_30i8srgdvm3rar6n8rcpr445pa